GDF-8 Myostatin Inhibitor

Early human Muscle & Bone Health 3 sources

GDF-8 (Growth Differentiation Factor 8), commonly known as myostatin, is a protein that naturally inhibits muscle growth. Myostatin inhibitors are compounds designed to block this protein, thereby promoting significant muscle hypertrophy and preventing muscle wasting in various research models.

01Dosing reference

Amount

1 mg - 3 mg (highly variable depending on specific peptide/antibody)

Frequency

Once weekly to bi-weekly in research settings

Cycle

4-8 weeks

Reference figures, not a recommendationThese values reflect amounts described in the literature and vendor documentation this database indexes. Use the reconstitution calculator to convert them into syringe units.

02Mechanism of action

Myostatin (GDF-8) Binding

The inhibitor binds directly to myostatin or blocks its receptor (ActRIIB), preventing myostatin from exerting its normal signaling.

Disinhibition of Muscle Growth

By blocking myostatin, the natural brake on muscle growth is removed, leading to increased protein synthesis and muscle fiber hypertrophy.

Research Implication

This mechanism is highly researched for treating severe muscle-wasting conditions like muscular dystrophy, sarcopenia, and cachexia.

03Human evidence

Increased lean body mass in healthy volunteers and muscular dystrophy patients.

Early clinical trials (e.g., with ACE-031 or MYO-029) showed some increases in muscle mass, but trials were often halted due to adverse effects like nosebleeds or dilated blood vessels.

Potential for treating age-related sarcopenia and cachexia.

Various monoclonal antibodies against myostatin have been tested in older adults, showing modest improvements in lean mass but mixed results regarding functional strength improvements.

04Preclinical evidence

Massive muscle hypertrophy in animal models.

Mice genetically engineered to lack myostatin ('mighty mice') or treated with inhibitors show up to a 2-fold increase in muscle mass.

Prevention of muscle atrophy in disease models.

In mouse models of muscular dystrophy, myostatin inhibition preserves muscle tissue and improves force generation.

05What is known vs. unknown

Reasonably established

Myostatin is a negative regulator of skeletal muscle mass.
Inhibiting myostatin leads to significant muscle hypertrophy in animal models.
Human trials have shown increases in lean mass but often struggle with side effects or lack of functional strength improvements.
Research is heavily focused on muscular dystrophy and age-related muscle loss.

Unknowns & limits

Long-term safety of systemic myostatin inhibition in humans is not fully established.
It is unclear if the increased muscle mass translates to proportional increases in functional strength in humans.
Potential off-target effects on other tissues, such as the heart or blood vessels, remain a significant concern.

06Safety & regulatory context

Regulatory statusMyostatin inhibitors are largely experimental and not FDA-approved for general use or bodybuilding. Clinical trials of some candidates (like ACE-031) were discontinued due to adverse events, including epistaxis (nosebleeds) and telangiectasias (dilated blood vessels). They are strictly for research purposes and are actively investigated for severe muscle-wasting conditions.

07Compared with Follistatin

GDF-8 Myostatin Inhibitor vs. Follistatin

Key difference

Follistatin is a naturally occurring protein that binds and neutralizes myostatin (and other TGF-beta family members), whereas specific GDF-8 inhibitors (like monoclonal antibodies) are designed to target myostatin exclusively.

When researchers discuss each

Follistatin is discussed in the context of gene therapy and broad TGF-beta inhibition, while specific GDF-8 inhibitors are discussed for targeted pharmacological interventions.

08Glossary

Myostatin (GDF-8)

A protein produced and released by myocytes that acts on muscle cells' autocrine function to inhibit muscle growth.

Hypertrophy

The enlargement of an organ or tissue from the increase in size of its cells, specifically muscle cells in this context.

Sarcopenia

The degenerative loss of skeletal muscle mass, quality, and strength associated with aging.

09Knowledge check

Q1What is the primary biological function of myostatin (GDF-8) in the body?

Q2Why were some early clinical trials for myostatin inhibitors like ACE-031 halted?

Q3Which statement best reflects a documented limitation of the human clinical evidence for GDF-8 (myostatin) inhibitors?

Q4According to the dossier's comparison, how does follistatin differ from specific GDF-8 (myostatin) inhibitors in research discussions?

Q5Which statement accurately summarizes the safety and regulatory context for myostatin inhibitors given in the dossier?

10Sources

More in Muscle & Bone Health

See all

IGF-1 LR3

Muscle & Bone Health

Early human

IGF-1 LR3 is a synthetic, modified version of Insulin-like Growth Factor-1 with an extended half-life and increased potency. Research highlights its ability to promote muscle cell hyperplasia (growth of new muscle cells), enhance protein synthesis, and improve recovery by resisting deactivation by IGF-binding proteins.

20-50 mcg per day

ACE-031

Muscle & Bone Health

Early human

ACE-031 is an investigational protein therapeutic designed to build muscle and increase strength by inhibiting signaling through the activin receptor type IIB (ActRIIB). Research primarily focused on its potential to treat muscle-wasting diseases like Duchenne muscular dystrophy, though clinical trials were halted due to safety concerns involving bleeding.

1-3 mg/kg (in clinical trial settings)

IGF-1 DES

Muscle & Bone Health

Preclinical only

IGF-1 DES (DES(1-3)IGF-1) is a truncated variant of Insulin-like Growth Factor 1 that lacks the first three amino acids at the N-terminus. This structural modification prevents it from binding to IGF-binding proteins (IGFBPs), resulting in a highly potent, fast-acting peptide. Research primarily focuses on its ability to stimulate cellular hyperplasia and localized tissue repair, particularly in skeletal muscle and gut mucosa.

20-50 mcg per day (often split bilaterally into target muscles)

Research and educational use onlyNothing on this site is medical advice, a prescription, or a recommendation for human use. Compounds documented here are research chemicals. Consult a qualified clinician before making any health decision.